PD-L1 expression according to the EGFR status in primary lung adenocarcinoma

Kazuki Takada, Gouji Toyokawa, Tetsuzo Tagawa, Kenichi Kohashi, Mototsugu Shimokawa, Takaki Akamine, Shinkichi Takamori, Fumihiko Hirai, Fumihiro Shoji, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung adenocarcinoma. However, the association between PD-L1 expression and EGFR mutation site in EGFR mutation-positive lung adenocarcinoma is unclear. Materials and methods We retrospectively examined the relationship between PD-L1 expression and EGFR status in 441 surgically resected primary lung adenocarcinomas. Membrane PD-L1 expression on tumor cells was evaluated by immunohistochemical analysis using a PD-L1 antibody (clone SP142) and defined by tumor proportion scores (TPSs) of 0%, 1–4%, 5–49%, and ≥50%, respectively. Results Two hundred and eighteen (49.4%) patients had wild-type EGFR, and 223 (50.6%) had mutant EGFR—98 (44.0%) with exon 19 deletion, 116 (52.0%) with exon 21 L858R point mutation, and nine (4.0%) with another EGFR mutation. Overall, Fisher's exact test showed that PD-L1 positivity was associated with wild-type EGFR, and there was only one case with PD-L1 TPS ≥50% among the cases with mutant EGFR. The analysis of cases with mutant EGFR indicated no significant association between EGFR mutation site and PD-L1 expression. However, the prevalence of PD-L1 TPS 5–49% was higher among patients with EGFR exon 19 deletion than with EGFR exon 21 L858R point mutation. Conclusions PD-L1 expression was significantly associated with wild-type EGFR, and PD-L1 TPS ≥50% seldom overlaps with presence of driver oncogene EGFR. There was no significant difference in PD-L1 expression among the EGFR mutation sites

元の言語英語
ページ(範囲)1-6
ページ数6
ジャーナルLung Cancer
116
DOI
出版物ステータス出版済み - 2 2018

Fingerprint

Epidermal Growth Factor Receptor
Cell Death
Ligands
Exons
Mutation
Adenocarcinoma of lung
Neoplasms
Point Mutation
Oncogenes
Clone Cells
Smoking

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

これを引用

PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. / Takada, Kazuki; Toyokawa, Gouji; Tagawa, Tetsuzo; Kohashi, Kenichi; Shimokawa, Mototsugu; Akamine, Takaki; Takamori, Shinkichi; Hirai, Fumihiko; Shoji, Fumihiro; Okamoto, Tatsuro; Oda, Yoshinao; Maehara, Yoshihiko.

:: Lung Cancer, 巻 116, 02.2018, p. 1-6.

研究成果: ジャーナルへの寄稿記事

Takada, K, Toyokawa, G, Tagawa, T, Kohashi, K, Shimokawa, M, Akamine, T, Takamori, S, Hirai, F, Shoji, F, Okamoto, T, Oda, Y & Maehara, Y 2018, 'PD-L1 expression according to the EGFR status in primary lung adenocarcinoma', Lung Cancer, 巻. 116, pp. 1-6. https://doi.org/10.1016/j.lungcan.2017.12.003
Takada, Kazuki ; Toyokawa, Gouji ; Tagawa, Tetsuzo ; Kohashi, Kenichi ; Shimokawa, Mototsugu ; Akamine, Takaki ; Takamori, Shinkichi ; Hirai, Fumihiko ; Shoji, Fumihiro ; Okamoto, Tatsuro ; Oda, Yoshinao ; Maehara, Yoshihiko. / PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. :: Lung Cancer. 2018 ; 巻 116. pp. 1-6.
@article{1399085f19c6499995f449c04d10831c,
title = "PD-L1 expression according to the EGFR status in primary lung adenocarcinoma",
abstract = "Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung adenocarcinoma. However, the association between PD-L1 expression and EGFR mutation site in EGFR mutation-positive lung adenocarcinoma is unclear. Materials and methods We retrospectively examined the relationship between PD-L1 expression and EGFR status in 441 surgically resected primary lung adenocarcinomas. Membrane PD-L1 expression on tumor cells was evaluated by immunohistochemical analysis using a PD-L1 antibody (clone SP142) and defined by tumor proportion scores (TPSs) of 0{\%}, 1–4{\%}, 5–49{\%}, and ≥50{\%}, respectively. Results Two hundred and eighteen (49.4{\%}) patients had wild-type EGFR, and 223 (50.6{\%}) had mutant EGFR—98 (44.0{\%}) with exon 19 deletion, 116 (52.0{\%}) with exon 21 L858R point mutation, and nine (4.0{\%}) with another EGFR mutation. Overall, Fisher's exact test showed that PD-L1 positivity was associated with wild-type EGFR, and there was only one case with PD-L1 TPS ≥50{\%} among the cases with mutant EGFR. The analysis of cases with mutant EGFR indicated no significant association between EGFR mutation site and PD-L1 expression. However, the prevalence of PD-L1 TPS 5–49{\%} was higher among patients with EGFR exon 19 deletion than with EGFR exon 21 L858R point mutation. Conclusions PD-L1 expression was significantly associated with wild-type EGFR, and PD-L1 TPS ≥50{\%} seldom overlaps with presence of driver oncogene EGFR. There was no significant difference in PD-L1 expression among the EGFR mutation sites",
author = "Kazuki Takada and Gouji Toyokawa and Tetsuzo Tagawa and Kenichi Kohashi and Mototsugu Shimokawa and Takaki Akamine and Shinkichi Takamori and Fumihiko Hirai and Fumihiro Shoji and Tatsuro Okamoto and Yoshinao Oda and Yoshihiko Maehara",
year = "2018",
month = "2",
doi = "10.1016/j.lungcan.2017.12.003",
language = "English",
volume = "116",
pages = "1--6",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - PD-L1 expression according to the EGFR status in primary lung adenocarcinoma

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Tagawa, Tetsuzo

AU - Kohashi, Kenichi

AU - Shimokawa, Mototsugu

AU - Akamine, Takaki

AU - Takamori, Shinkichi

AU - Hirai, Fumihiko

AU - Shoji, Fumihiro

AU - Okamoto, Tatsuro

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/2

Y1 - 2018/2

N2 - Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung adenocarcinoma. However, the association between PD-L1 expression and EGFR mutation site in EGFR mutation-positive lung adenocarcinoma is unclear. Materials and methods We retrospectively examined the relationship between PD-L1 expression and EGFR status in 441 surgically resected primary lung adenocarcinomas. Membrane PD-L1 expression on tumor cells was evaluated by immunohistochemical analysis using a PD-L1 antibody (clone SP142) and defined by tumor proportion scores (TPSs) of 0%, 1–4%, 5–49%, and ≥50%, respectively. Results Two hundred and eighteen (49.4%) patients had wild-type EGFR, and 223 (50.6%) had mutant EGFR—98 (44.0%) with exon 19 deletion, 116 (52.0%) with exon 21 L858R point mutation, and nine (4.0%) with another EGFR mutation. Overall, Fisher's exact test showed that PD-L1 positivity was associated with wild-type EGFR, and there was only one case with PD-L1 TPS ≥50% among the cases with mutant EGFR. The analysis of cases with mutant EGFR indicated no significant association between EGFR mutation site and PD-L1 expression. However, the prevalence of PD-L1 TPS 5–49% was higher among patients with EGFR exon 19 deletion than with EGFR exon 21 L858R point mutation. Conclusions PD-L1 expression was significantly associated with wild-type EGFR, and PD-L1 TPS ≥50% seldom overlaps with presence of driver oncogene EGFR. There was no significant difference in PD-L1 expression among the EGFR mutation sites

AB - Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung adenocarcinoma. However, the association between PD-L1 expression and EGFR mutation site in EGFR mutation-positive lung adenocarcinoma is unclear. Materials and methods We retrospectively examined the relationship between PD-L1 expression and EGFR status in 441 surgically resected primary lung adenocarcinomas. Membrane PD-L1 expression on tumor cells was evaluated by immunohistochemical analysis using a PD-L1 antibody (clone SP142) and defined by tumor proportion scores (TPSs) of 0%, 1–4%, 5–49%, and ≥50%, respectively. Results Two hundred and eighteen (49.4%) patients had wild-type EGFR, and 223 (50.6%) had mutant EGFR—98 (44.0%) with exon 19 deletion, 116 (52.0%) with exon 21 L858R point mutation, and nine (4.0%) with another EGFR mutation. Overall, Fisher's exact test showed that PD-L1 positivity was associated with wild-type EGFR, and there was only one case with PD-L1 TPS ≥50% among the cases with mutant EGFR. The analysis of cases with mutant EGFR indicated no significant association between EGFR mutation site and PD-L1 expression. However, the prevalence of PD-L1 TPS 5–49% was higher among patients with EGFR exon 19 deletion than with EGFR exon 21 L858R point mutation. Conclusions PD-L1 expression was significantly associated with wild-type EGFR, and PD-L1 TPS ≥50% seldom overlaps with presence of driver oncogene EGFR. There was no significant difference in PD-L1 expression among the EGFR mutation sites

UR - http://www.scopus.com/inward/record.url?scp=85037624244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037624244&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.12.003

DO - 10.1016/j.lungcan.2017.12.003

M3 - Article

C2 - 29413045

AN - SCOPUS:85037624244

VL - 116

SP - 1

EP - 6

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -